Drug intelligence / Profile preview

UA19

Development stage: Preclinical
Lead developer: Wuhan Kangfude Biotechnology

Overview

UA19 is a preclinical drug candidate developed by the Kangfude Urolithiasis Institute (Wuhan Kangfude Biological Technology) for the treatment of hyperoxalemia and gout. The candidate is part of a pipeline focused on metabolic and urological health, though its specific modality and mechanism of action have not been disclosed. It is currently in the early stages of development, moving toward Investigational New Drug (IND) filing.

Beyond the preview

Go deeper on UA19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UA19.

Explore the full profile